Treating the Primary in High vs Low Volume Hormone Sensitive Disease

Imaging Modalities to Treat Node-Positive Disease

The Risk of Dose De-intensifying Treatment, Bone Health in Prostate Cancer

Integrating Genomics and Genetics into Clinical Care for Prostate Cancer, A Pathologist's Perspective

State-of-the-industry video lectures by leading urology experts
Featured Videos

#AUA14 - Treatment practice patterns in metastatic castration-resistant prostate cancer patients prior to receiving sipuleucel-T: Data from PROCEED - Session Highlights

ORLANDO, FL USA ( - During the “Advanced Prostate Cancer II” session, Dr. Matthew Cooperberg presented data from PROCEED, an ongoing Phase 4 registry of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (ST). ST is an immunotherapy that targets prostatic acid phosphatase. While PROCEED is ongoing, baseline demographics and treatment practice patterns were reported. Data from approximately 1 400 patients was included. The majority of patients were Caucasian (87.6%) with a median age of 72 years. Median baseline PSA was 16.1 ng/mL, and 49.9% of patients had Gleason ≥ 8 disease.

auaClose to three-quarters of patients underwent local therapy, the majority with radiation (56.9%) or radical prostatectomy (35.8%). Fifteen percent of patients received prior chemotherapy (12.4% docetaxel). Patients treated in oncology practices more commonly received prior oral anti-androgen (67%) and chemotherapy (19%) compared to patients treated in urology practices (41.7% and 5.9%, respectively). The preliminary data from PROCEED provides a window into current treatment patterns for mCRPC. Dr. Cooperberg concluded that PROCEED will continue to provide useful information for tracking practice patterns and care trends for men with mCRPC prior and subsequent to treatment with ST.

Click HERE to view the poster from this session

Presented by Matthew Cooperberg, MD, MPH at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

University of California, San Francisco USA

Written by Jeffrey J. Tomaszewski, MD, medical writer for

Conference Coverage
Recent data from conferences worldwide
  • 2019 Annual Congress / October 17 - October 20 / Athens, Greece
  • 2019 Annual Meeting / October 3 - October 5 / Aarhus, Denmark
  • 2019 Annual Congress / September 27 - October 1 / Barcelona, Spain
  • 2019 Biennial Meeting / August 29-31 / Basel, Switzerland
  • 2019 Think Tank / August 8-10 / Washington, DC
  • 2019 Annual Meeting / May 31 - June 6 / Chicago, IL
  • 2019 Annual Meeting / May 3-6 / Chicago, IL
  • 2019 World Congress / May 1-3 / Liverpool, United Kingdom
  • 2019 Symposium / April 1-4 / Ottawa, ON
Publications focusing on urologic cancer treatments through original manuscripts

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.